Last update:
The first vaccine against indigenous dengue of India, ‘Dengiall’, developed by ICMR and Panacea Biotech, is in phase 3 tests and can be greedy in mid -2026, says former director of ICMR Balram Bhargava
Essays are being carried out in 19 centers in 18 union states and territories, which involve more than 10,335 healthy participants. (Representative/PTI file)
India is expected to have its first vaccine against indigenous dengue for next year, according to the former director of the Indian Medical Research Council (ICMR), Balram Bhargava. Bhargava shared this significant update of the roof of a vaccine program in Science City, Kolkata, Tuesday.
Currently, phase 3 clinical trials of the vaccine, jointly developed by ICMR and Panacea Biotech, are underway and have shown promising results so far.
The vaccine, called ‘Dengiall’, is the first indigenous tetravalent denguer vaccine of India. Essays are being carried out in 19 centers in 18 union states and territories, which involve more than 10,335 healthy participants.
If phase 3 tests are successful, the vaccine could be available in mid -2026, Althegh ICMR has not yet confirmed its availability. Health experts believe that the introduction of this vaccine could significantly help control dengue in India.
Dengue, a viral infection transmitted through the bite of infected mosquitoes, causes high fever and a reduction in platelet count. If it’s not quickly, it can be fatal. The disease is the most frequent duration of the rainy season, partly in states such as Western Bengal, Uttar Pradesh, Rajasthan, Bihar, Delhi, Gujarat, Kerala, Karnataka and Tamil Nadu, resulting in numerous deaths. It is anticipated that the arrival of this vaccine provides crucial protection against dengue.
